Pirfenidone use in patients with idiopathic pulmonary fibrosis may be linked to a lower incidence of lung cancer. Learn more.
Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC ...
No safety concerns emerged in part one of the phase 1 trial assessing CS014, a histone deacetylase inhibitor that has ...
About Avalyn Pharma. Avalyn is a biopharmaceutical company developing inhaled therapies for the treatment of rare respiratory ...
For treating pulmonary fibrosis, presently the pharmacological arsenal involves only two drugs, pirfenidone and nintedanib, which work to slow down the disease progression but do not completely ...
Dysbiosis is the condition of having imbalances in the microbial communities either in or on the body. Dysbiosis is associated with many diseases, such as inflammatory bowel disease and chronic ...
Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Pirfenidone (CAS 53179-13-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...
Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Pirfenidone (CAS 53179-13-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...
He talks about the importance of knowing your history. “Black History Month is about living history. It is not just recognizing some ancient African emperor, which we have," Dr. Miller-Jones ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results